

7. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *Lancet*. 2015;386:249-257.

8. Reuss A, du Bois A, Harter P, et al. TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). *Int J Gynecol Cancer*. 2019;29(8):1327-1331.

9. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med*. 1996;335:1950-1955.

10. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med*. 2006;354:34-43.

11. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern cooperative Oncology group. *J Clin Oncol*. 2001;19:1001-1007.

12. Landrum LM, Jawa J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2013;130(1):8-12.

13. Tewari J, Jawa J, Salani R, et al. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced

ced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study. *Gynecol Oncol*. 2013;130(1):4.

14. Lim MCh, Chang SJ, Park B, et al. HIPEC for Ovarian Cancer Collaborators Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. *JAMA Surg*. 2022; 157(5):374-383.

15. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. *N Engl J Med*. 2018;378(3):230-240.

16. Aronson SL, Lpez-Yurda M, Koole SN, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer/OVHIPEC-1: final survival analysis of a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2023;24(10):1109-1118.

17. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications and prognostic value of peritoneal carcinomatosis. *Ann Surg Oncol*. 2009;16(5):1324-1330.

18. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO Austria, and MITO. *Int J Gynecol Cancer*. 2011;21(2):289-295.

19. Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery

and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. *Ann Surg Oncol*. 2012;19:4052-4058.

20. Spiliotis J, Vaxevanidou A, Sergouniotis F, et al. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. *J BUON*. 2011;16(1):74-9.

21. Fagotti A, Constantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case control study on survival in patients with two year follow-up. *Gynecol. Oncol*. 2012;127(3):502-505.

22. Classe JM, Meeus P, Leblanc E, et al. Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the CHIPOR randomized phase III trial. *J Clin Oncol*. 2023;41(suppl 16):5510.

23. Chi DS, McCaughy K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. *Cancer*. 2006;109(9):1933-1939.

24. Rosen B, Laframboise S, Ferguson S, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. *Gynecol Oncol*. 2014;134(3):462-467.

25. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med*. 2010;363(10):943-953.

Poděkování za spolupráci

Rádi bychom v tomto předvánočním čase vyjádřili poděkování všem, kteří se podílejí na vzniku časopisu Onkologie.

Děkujeme **členům redakční rady** za četné nápady, podněty, připomínky a doporučení, díky kterým se může časopis neustále rozvíjet.

Děkujeme **autorům**, kteří mezi množstvím dalších povinností našli čas a energii na napsání článků. A – last but not least – děkujeme **i recenzentům**, díky nimž si časopis udržuje odbornou kvalitu, a to: prof. MUDr. Tomáš Büchler, Ph.D., MUDr. Eduard Cmunt, CSc., MUDr. Martin Čerňan, Ph.D., prof. MUDr. Martin Doležel, Ph.D., MUDr. Miroslav Důra, Ph.D., MUDr. Michal Eid, doc. MUDr. Karel Ettler, CSc., MUDr. František Folber, Ph.D., MUDr. Stanislav John, MUDr. Bohdan Kadlec, Ph.D., MUDr. Jana Katolícká, Ph.D., MUDr. Jindřich Kopecký, Ph.D., Mgr. Pavla Kordulová, MUDr. Juraj Kultán, MUDr. Marián Liberko, MUDr. Jana Mergancová, Ph.D., MUDr. Monika Náležinská, MUDr. Zdeňka Pechačová, Ph.D., MUDr. Ján Podhorec, MUDr. Nátaľia Podstavková, doc. MUDr. Igor Sirák, Ph.D., MUDr. Martin Šimkovič, Ph.D., MUDr. Martin Špaček, Ph.D., MUDr. Martin Troubil, MUDr. Peter Turcsányi, Ph.D., doc. MUDr. David Vrána, Ph.D., MUDr. Miroslav Žiaran.

A děkujeme i vám – **čtenářům** – pro vás to děláme a díky vám nás tato práce baví.

redakce časopisu Onkologie